Moreover, in CRC, the combination of OCA plus nitazoxanide (NTZ), an antiparasitic drug, exerts synergistic tumor inhibition both in vitro and in vivo by co-operatively upregulating the expression of small heterodimer partner (SHP) and abrogating β-catenin expression [208]. The gene discussed is NR0B2; the disease is colorectal carcinoma.